Andere talen Karyopharm Therapeutics Inc.

Aandelen

KPTI

US48576U1060

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,09 ^USD	0,00%		-0,91%	+26,01%

13/03	Transcript : Karyopharm Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM
29/02	Transcript : Karyopharm Therapeutics Inc., Q4 2023 Earnings Call, Feb 29, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting	24/04
Karyopharm Therapeutics : April 19, 2024	19/04
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/04
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences	06/03
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	04/03
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/03
Karyopharm Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress	01/03
Karyopharm Therapeutics: Q4 Earnings Snapshot	29/02
Karyopharm Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q4 Revenue $33.7M, vs. Street Est of $33.6M	29/02
Karyopharm Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024	29/02
North American Morning Briefing : Fed's Preferred -2-	29/02
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024	22/02
North American Morning Briefing : Stock Futures -2-	21/02
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/02
Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023	08/01
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives	08/01
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	03/01
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference	03/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Karyopharm Therapeutics Inc.

Aandelen

KPTI

US48576U1060

Andere talen

Filters